In a recent interview at CPHI Europe 2025, J.D. Mowery, President of Bora Pharmaceuticals, highlighted key hurdles and advancements within the biopharmaceutical industry. The conversation delved into the pressing need for global sustainability standards, the challenges of implementing artificial intelligence (AI), and the imperative for maturity in outsourcing partnerships.
Mowery emphasised the critical importance of global standardisation in addressing environmental impacts across biopharma supply chains and manufacturing facilities. By establishing common criteria, both innovators and Contract Development and Manufacturing Organizations (CDMOs) can align their performance metrics. This alignment enables biopharma companies to select partners who uphold similar sustainability standards, fostering transparency and accountability in the industry.
The implementation of AI in biopharma operations poses significant challenges, primarily related to data readiness. Mowery highlighted that organisations often underestimate the complexity of consolidating and cleansing dispersed data prior to leveraging AI effectively. Just as transitioning from paper to digital formats required meticulous data hygiene, the success of AI tools hinges on the quality of the underlying data. This initial data consolidation effort is crucial for realising the full potential of AI technologies.
Moreover, Mowery underscored that the biopharma sector lags behind other industries, such as automotive and computer manufacturing, in terms of outsourcing maturity. Economically, increased outsourcing can enable CDMOs to optimise overhead costs across multiple products and clients. However, building trust with the biopharma industry remains a significant barrier to expanding outsourcing opportunities. Maintaining operational excellence, particularly in on-time delivery rates, is key for CDMOs to earn the trust of biopharma companies.
In striving for outsourcing maturity, the biopharma sector must recognise the benefits of collaboration and shared resources offered by CDMOs. By outsourcing more production processes, biopharma companies can benefit from cost efficiencies and operational scalability. This shift towards increased outsourcing requires a cultural shift towards trust and transparency between biopharma companies and CDMOs.
The path to enhancing sustainability, implementing AI, and fostering robust CDMO partnerships necessitates a concerted industry-wide effort towards standardisation and operational excellence. By aligning on global sustainability standards, streamlining AI implementation processes, and nurturing trust in outsourcing relationships, the biopharma sector can drive innovation and efficiency across the value chain.
Key Takeaways:
1. Global standardisation is crucial for promoting sustainability and transparency in biopharma supply chains.
2. Data readiness and cleansing are foundational steps for unlocking the full potential of AI in biopharma operations.
3. Building trust through operational excellence is essential for fostering mature outsourcing partnerships in the biopharma industry.
Tags: formulation, biopharma, regulatory
Read more on pharmtech.com